Ibrutinib/rituximab is superior to FCR for younger CLL patients in the frontline setting
Should standard chemotherapy regimens be altered in favor of small molecules? iFCG for frontline CLL
Ibrutinib and FCR chemoimmunotherapy: improving complete remission in CLL patients?
Debate on the best first-line treatment for unmutated CLL: opinions from across the Atlantic